Overall, our study suggests that different concentrations of Fuzi can be used in different treatment stages of AD by regulating the complex regulation network with the core of GRIN1 and MAPK1. Besides, the four compounds of Fuzi targeting GRIN1 and MAPK1 may be the key to anti-AD medicine. This evidence concerns the gene GRIN1 and Alzheimer disease.